1
|
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. [Update of the 2021 recommendations for the management and follow-up of adult asthmatic patients under the guidance of the French Society of Pulmonology and the Paediatric Society of Pulmonology and Allergology. Long version]. Rev Mal Respir 2021; 38:1048-1083. [PMID: 34799211 DOI: 10.1016/j.rmr.2021.08.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/17/2021] [Indexed: 11/22/2022]
Affiliation(s)
- C Raherison-Semjen
- Université de Bordeaux, INSERM UMR 1219, Epicene Team, Bordeaux, France.
| | - L Guilleminault
- Pôle des voies respiratoires, CHU de Toulouse, Toulouse, France; Institut toulousain des maladies infectieuses et inflammatoires (Infinity), INSERM, UMR1291, CNRS UMR5051, université Toulouse III, CRISALIS F-CRIN, Toulouse, France
| | | | - C Chenivesse
- CHRU de Lille, service de pneumo-allergologie, 59000 Lille, France
| | - A De Oliveira
- Sorbonne université, département de médecine générale, Paris, France
| | - A Izadifar
- Département de pneumologie, centre cardiologique du Nord, Saint-Denis, France
| | - A Lorenzo
- Sorbonne université, département de médecine générale, Paris, France
| | - C Nocent
- CHG Côte Basque, Bayonne, France
| | - J P Oster
- Service de pneumologie, centre hospitalier Louis-Pasteur, Colmar, France
| | - M Padovani
- Espace Santé Ii, La Seyne-sur-Mer, France
| | - T Perez
- CHRU de Lille, service d'explorations fonctionnelles, 59000 Lille, France
| | - M Russier
- Service de pneumo-allergologie, CHR Orléans, Orléans, France
| | - M Steinecker
- Sorbonne université, département de médecine générale, Paris, France
| | - A Didier
- Université de Bordeaux, INSERM UMR 1219, Epicene Team, Bordeaux, France; Pôle des voies respiratoires, CHU de Toulouse, Toulouse, France
| |
Collapse
|
2
|
Raherison-Semjen C, Guilleminault L, Billiart I, Chenivesse C, De Oliveira A, Izadifar A, Lorenzo A, Nocent C, Oster JP, Padovani M, Perez T, Russier M, Steinecker M, Didier A. [Updated guidelines for management of asthmatic patients (from 12 years and older). Short version]. Rev Mal Respir 2021; 38:e1-e13. [PMID: 34840037 DOI: 10.1016/j.rmr.2021.08.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 06/17/2021] [Indexed: 11/26/2022]
Affiliation(s)
- C Raherison-Semjen
- Inserm UMR 1219, Epicene Team, université de Bordeaux, Bordeaux, France.
| | - L Guilleminault
- Pôle des voies respiratoires, CHU de Toulouse, Toulouse, France; Institut Toulousain des maladies infectieuses et inflammatoires (Infinity) Inserm UMR1291 - CNRS UMR5051 - université Toulouse III, CRISALIS F-CRIN, Toulouse, France
| | | | - C Chenivesse
- Service de pneumo-allergologie, CHRU de Lille, 59000 Lille, France
| | - A De Oliveira
- Département de médecine générale, Sorbonne université, Paris, France
| | - A Izadifar
- Département de pneumologie du centre cardiologique du Nord, Saint-Denis, France
| | - A Lorenzo
- Département de médecine générale, Sorbonne université, Paris, France
| | - C Nocent
- CHG Côte Basque, Bayonne, France
| | - J P Oster
- Service de pneumologie, centre hospitalier Louis Pasteur, Colmar, France
| | - M Padovani
- Espace Sante Ii, La Seyne-sur-Mer, France
| | - T Perez
- Service d'explorations fonctionnelles, CHRU de Lille, 59000 Lille, France
| | - M Russier
- Service pneumo allergologie, CHR Orléans, Orléans, France
| | - M Steinecker
- Département de médecine générale, Sorbonne université, Paris, France
| | - A Didier
- Inserm UMR 1219, Epicene Team, université de Bordeaux, Bordeaux, France; Pôle des voies respiratoires, CHU de Toulouse, Toulouse, France
| |
Collapse
|
3
|
Payen T, Trédaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec JL, Molinier O, Debieuvre D. Real world data of efficacy and safety of erlotinib as first-line TKI treatment in EGFR mutation-positive advanced non-small cell lung cancer: Results from the EGFR-2013-CPHG study. Respir Med Res 2020; 80:100795. [PMID: 34242973 DOI: 10.1016/j.resmer.2020.100795] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 09/22/2020] [Accepted: 10/09/2020] [Indexed: 11/29/2022]
Abstract
BACKGROUND Phase III clinical trials have demonstrated the merits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in the treatment of non-small cell lung cancer (NSCLC) patients with EGFR-activating mutations. Using a cohort of unselected patients treated with erlotinib, we sought to further describe patient and tumour characteristics, and to evaluate their progression-free survival (PFS) and overall survival (OS). METHODS Overall, 44 pulmonologists included patients with the required characteristics as follows: Stage IIIB-IV NSCLC, EGFR-activating mutation, age≥18 years, and having to start erlotinib therapy or receiving erlotinib therapy as the first-line TKI, regardless of treatment-line. The analyses were performed using R software, with survival rates calculated according to the Kaplan-Meier method. RESULTS A total of 177 patients, aged 72 years on average, were enrolled over a 2-year period. The cohort included 123 women (69.5%), 158 Caucasians (89.3%), 112 non-smokers (63.2%), and 167 adenocarcinomas (94.3%), at either stage IIIB (21) or IV (156), with a good performance status (PS 0-1, 127). Overall, 40 exhibited brain metastases at baseline (22.6%), while 75 had undergone earlier treatment (42.4%). Median PFS was 11.7 months and OS 25.8 months, with respectively a 1-year rate of 48.6% and 74%. The risk of death correlated with ECOG status (PS=2, HR=4.48, P<0.001) but not with brain metastasis (HR=1.67, P=0.278). CONCLUSIONS This study has confirmed erlotinib's efficacy and safety for unselected patients, with PFS and OS comparable to those obtained in phase III trials.
Collapse
Affiliation(s)
- T Payen
- Respiratory Medicine Department, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Hôpital Emile-Muller, 20, rue du Dr-Laënnec, BP 1370, 68070 Mulhouse cedex, France
| | - J Trédaniel
- Respiratory Medicine and Thoracic Oncology Department, Groupe Hospitalier Paris Saint-Joseph, Paris, France; Paris Descartes University, Sorbonne Paris cité, Paris, France; INSERM Unit UMR-S 1124, Toxicology, Pharmacology and Cell Signalling, Paris, France
| | - L Moreau
- Respiratory Medicine Department, Hôpitaux Civils de Colmar, 68024 Colmar, France
| | - S Larivé
- Respiratory Medicine Department, Centre hospitalier de Macon - site des Chanaux, 71018 Macon, France
| | - J Le Treut
- Respiratory Medicine Department, Hôpital Européen, 13003 Marseille, France
| | - C Nocent
- Respiratory Medicine Department, Centre Hospitalier de la Côte Basque, 64109 Bayonne, France
| | - S Hominal
- Respiratory Medicine Department, Centre Hospitalier Annecy-Genevois, 74000 Annecy, France
| | - V Grangeon
- Respiratory Medicine Department, Centre Hospitalier de Roanne, 42300 Roanne, France
| | - J-L Bizec
- Respiratory Medicine Department, Centre Hospitalier Bretagne-Atlantique, 56017 Vannes, France
| | - O Molinier
- Respiratory Medicine Department, Centre Hospitalier du Mans, 72 037 Le Mans, France
| | - D Debieuvre
- Respiratory Medicine Department, Groupe Hospitalier de la Région Mulhouse Sud-Alsace, Hôpital Emile-Muller, 20, rue du Dr-Laënnec, BP 1370, 68070 Mulhouse cedex, France.
| |
Collapse
|
4
|
Debieuvre D, Tredaniel J, Moreau L, Larivé S, Le Treut J, Nocent C, Hominal S, Grangeon V, Bizec J, Molinier O, Payen T. EP1.01-05 EGFR-2013-CPHG, a Real-World Study of EGFR Mutant Advanced Non-Small-Cell Lung Cancer Patients Treated with Erlotinib. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1988] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
5
|
Taillé C, Pison C, Nocent C, Devouassoux G, Prud'homme A, Gruber A, Gunsoy N, Albers F. [Patients in the IDEAL cohort: A snapshot of severe asthma in France]. Rev Mal Respir 2018; 36:179-190. [PMID: 30429093 DOI: 10.1016/j.rmr.2018.10.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2018] [Accepted: 06/18/2018] [Indexed: 12/15/2022]
Abstract
INTRODUCTION This paper reports the French data from a post-hoc analysis of the international IDEAL study, which aimed to describe a recent cohort of patients with severe asthma, the impact of the disease on quality of life, as well as the population of patients eligible for treatment with omalizumab, mepolizumab and reslizumab. METHODS Eligible patients were≥12 years of age, with severe asthma (GINA steps 4 and 5). RESULTS A total of 129 patients were included in this post-hoc analysis. Their mean age was 53 years, the majority were overweight, they were mainly women (64%) and had at least one medical comorbidity (85%). More than half had suffered from asthma for more than 25 years and were non-smokers. Lung function was moderately impaired. Blood eosinophil count was≥150 cells/μL in 66% of patients,≥300 cells/μL in 34% of patients, and≥500 cells/μL in 12% of patients. One out of three patients was currently treated with omalizumab and 24% had maintenance oral corticosteroids. Asthma was poorly controlled with a negative impact on quality of life (ACQ≥1.5) in 67% of patients. In this population 40% of patients were eligible for omalizumab, 27% for mepolizumab and 2% for reslizumab. CONCLUSIONS These findings show that a considerable proportion of patients with severe asthma remain uncontrolled and are not eligible for any of the available biological treatments. This underlines the need for therapeutic innovations in this disease.
Collapse
Affiliation(s)
- C Taillé
- Service de pneumologie, centre de référence constitutif des maladies pulmonaires rares, DHU FIRE, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex 18, France; Inserm U1152, université Paris-Diderot, Labex Inflamex, 75018 Paris, France.
| | - C Pison
- Service hospitalier universitaire pneumologie physiologie, pôle thorax et vaisseaux, université Grenoble Alpes, CHU Grenoble Alpes, 38043 Grenoble cedex, France
| | - C Nocent
- Service de pneumologie, centre hospitalier de la côte basque, 64100 Bayonne, France
| | - G Devouassoux
- Service de pneumologie, hôpital de la Croix-Rousse, hospices civils de Lyon, 69004 Lyon, France
| | - A Prud'homme
- Service de pneumologie, centre hospitalier de Bigorre, Tarbes, 65013 Vic-en-Bigorre, France
| | - A Gruber
- GSK, 92500 Rueil-Malmaison, France
| | - N Gunsoy
- GSK, Stockley Park, Uxbridge, Royaume-Uni
| | - F Albers
- GSK, Research Triangle Park, NC, États-Unis
| |
Collapse
|
6
|
Portel L, Raherison C, Coëtmeur D, Didi T, Lemaire B, Maurer C, Nocent C, Osler J, Parrat E, Prud’homme A. France asthme sévère (FASE) : étude observationnelle transversale descriptive des patients atteints d’asthme sévère suivis dans les centres hospitaliers généraux. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Paganin F, Mangiapan G, Proust A, Prudhomme A, Attia J, Marchand-Adam S, Pellet F, Milhe F, Melloni B, Bernady A, Raspaud C, Nocent C, Berger P, Guilleminault L. Lung function parameters in omalizumab responder patients: An interesting tool? Allergy 2017; 72:1953-1961. [PMID: 28517027 DOI: 10.1111/all.13202] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/04/2017] [Indexed: 12/26/2022]
Abstract
BACKGROUND Omalizumab, an anti-IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and nonresponder patients remain inconclusive. The objective of this real-life study was to compare the changes in forced expiratory volume in 1 second (FEV1) of omalizumab responders and nonresponders at 6 months. METHODS A multicenter analysis was performed in 10 secondary and tertiary institutions. Lung function parameters (forced vital capacity (FVC), pre- and postbronchodilator FEV1, residual volume (RV), and total lung capacity (TLC) were determined at baseline and at 6 months. Omalizumab response was assessed at the 6-month visit. In the omalizumab responder patients, lung function parameters were also obtained at 12, 18, and 24 months. RESULTS Mean prebronchodilator FEV1 showed improvement in responders at 6 months, while a decrease was observed in nonresponders (+0.2±0.4 L and -0.1±0.4 L, respectively, P<.01). After an improvement at 6 months, pre- and postbronchodilator FEV1 remained stable at 12, 18, and 24 months. The FEV1/FVC remained unchanged over time, but the proportion of patients with an FEV1/FVC ratio <0.7 decreased at 6, 12, 18, and 24 months (55.2%, 54.0%, 54.0%, and 44.8%, respectively, P<.05). Mean RV values decreased at 6 months but increased at 12 months and 24 months (P<.05). Residual volume/total lung capacity (RV/TLC) ratio decreased at 6 months and remained unchanged at 24 months. CONCLUSION After omalizumab initiation, FEV1 improved at 6 months in responder patients and then remained stable for 2 years. RV and RV/TLC improved at 6 months.
Collapse
Affiliation(s)
- F. Paganin
- INSERM U 600, UMR 6212; Université de la Méditerranée.; Marseille France
- Université de la Réunion; St Denis France
| | - G. Mangiapan
- Service de Pneumologie; CHIC de Créteil; Créteil France
| | - A. Proust
- Service de Pneumologie; CHU de Nimes; Tarbes France
| | - A. Prudhomme
- Service de Pneumologie; CHG de Bigorre; Tarbes France
| | - J. Attia
- Cabinet de Pneumologie; Bastia France
| | | | - F. Pellet
- Cabinet de Pneumologie; Bordeaux France
| | - F. Milhe
- Service de Pneumologie; Polyclinique des Fleurs; Ollioules France
| | - B. Melloni
- Service de Pneumologie; CHU de Limoges; Limoges France
| | - A. Bernady
- Service de Pneumologie; Centre médical Toki Eder; Cambo les Bains France
| | - C. Raspaud
- Service de Pneumologie; Clinique Pasteur; Toulouse France
| | - C. Nocent
- Service de Pneumologie et d'allergologie; CH de la côte Basque; Bayonne France
| | - P. Berger
- Centre de Recherche Cardio-thoracique de Bordeaux; Univ. Bordeaux, U1045, CIC1401; Bordeaux France
- Centre de Recherche Cardio-thoracique de Bordeaux; INSERM, U1045, CIC1401; Bordeaux France
- Service d'Exploration Fonctionnelle Respiratoire; CHU de Bordeaux, CIC1401; Pessac France
| | - L. Guilleminault
- Université de la Réunion; St Denis France
- Service de Pneumologie; CHU Reunion/GHSR; Saint-Pierre France
- INSERM; UMR 1188 Diabète Athérothrombose Thérapies Réunion Océan Indien (DéTROI); Sainte-Clotilde France
| |
Collapse
|
8
|
Debieuvre D, Asselain B, Braud M, Fouret C, Larive S, Falchero L, Duval Y, Lemaire B, Farny M, Brun P, Dujon C, Nocent C, Dumont P, Le Lann P, Kassem GJ, Grivaux M. Good news for French NSCLC patients: Distance between chest and surgical departments did not impair outcome. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw381.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Taillé C, Raherison C, Sobaszek A, Thumerelle C, Prudhomme A, Biron E, Nocent C, Tillie-Leblond I. [Features of asthma in women: what is the relationship with hormonal status?]. Rev Mal Respir 2014; 31:469-77. [PMID: 25012033 DOI: 10.1016/j.rmr.2014.02.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2013] [Accepted: 12/31/2013] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The prevalence and control of asthma are modulated by hormonal changes in women, suggesting an influence of sex hormones on the airways. BACKGROUND The blood levels of both oestrogens and progesterone can modulate airway tone and inflammation. Asthma prevalence changes at puberty and the menopause, events also associated with modifications of adipose tissue and behaviour. Changes in lung function and asthma control are well documented during the menstrual cycle. However, an effect of hormone therapy on asthma control has not been demonstrated. PERSPECTIVE The effect of a targeted hormonal therapeutic intervention in menopausal asthma, a phenotype, which is frequently particularly severe, or in premenstrual asthma, should be evaluated by randomized trials. CONCLUSION Involvement of sex hormones and their cyclical variations in the characteristics of asthma in women is probable, despite lack of convincing data. However, no definitive protective or deleterious effect can be assigned. Complex interactions with adipose tissue, airways anatomy and the domestic or working environment must be taken into account to explain these differences.
Collapse
Affiliation(s)
- C Taillé
- Inserm U700, service de pneumologie, département hospitalo-universitaire FIRE, centre de compétence des maladies pulmonaires rares, hôpital Bichat, université Paris Diderot, AP-HP, 46, rue Henri-Huchard, 75877 Paris cedex, France.
| | - C Raherison
- U897 ISPED, service des maladies respiratoires, CHU de Bordeaux, université Bordeaux Segalen, 33076 Bordeaux, France
| | - A Sobaszek
- Service de médecine du travail et pathologies professionnelles, CHRU de Lille, 59000 Lille, France
| | - C Thumerelle
- Unité de pneumologie pédiatrique, hôpital Jeanne-de-Flandre, CHRU de Lille, 59000 Lille, France
| | - A Prudhomme
- Service de pneumologie, CHG de Bigorre, 65000 Tarbes, France
| | - E Biron
- Hôpital privé Jean-Mermoz, 69008 Lyon, France
| | - C Nocent
- Service de pneumologie, centre hospitalier de la Côte Basque, 64100 Bayonne, France
| | - I Tillie-Leblond
- Inserm U1019, service de pneumologie et d'immuno-allergologie, institut Pasteur de Lille, hôpital Calmette, université de Lille-2, CHRU, 59000 Lille, France
| |
Collapse
|
10
|
Abstract
International guidelines recommend prescription of inhaled corticosteroids to improve asthma control. Chronic secondary adrenal suppression due to inhaled corticosteroids has been described. We report a case of acute adrenal suppression due to drug interaction between Fluticasone and antiretroviral therapy in a HIV patient. Seeing an increased prevalence of hyperresponsiveness among HIV-infected men, we conclude that coprescription of Fluticasone and highly active antiretroviral therapy must be carefully controlled.
Collapse
Affiliation(s)
- C Nocent
- Service des Maladies Respiratoires, Hôpital Haut Lévèque, Pessac Cedex, France.
| | | | | | | |
Collapse
|
11
|
Lheureux M, Raherison C, Vernejoux JM, Nguyen L, Nocent C, Tunon De Lara M, Taytard A. Quality of life in lung cancer: does disclosure of the diagnosis have an impact? Lung Cancer 2004; 43:175-82. [PMID: 14739038 DOI: 10.1016/j.lungcan.2003.08.018] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Quality of life (QOL) is an important component of evaluation in oncology. Usually, QOL is used in phase III studies to compare two treatments. The aim of this trial was to evaluate the impact of the disclosure of the diagnosis of cancer on QOL by using the European Organisation for Research and Treatment of Cancer core Quality of Life Questionnaire (EORTC QLQ)-C30 questionnaire and the supplemental lung cancer-specific module QLQ-LC13. PATIENTS AND METHODS Patients hospitalised for exploration of an abnormal chest X-ray, with no previous history of cancer, a performance status < or =2, and able to fulfil the questionnaire were eligible. The patients answered the questionnaire two times: before (Q1) and after (Q2) the disclosure of the diagnosis. RESULTS Seventy patients answered at Q1 and Q2. After the disclosure, some scores deteriorated: arm pain (P=0.009), physical functioning (P=0.01), role functioning (P=0.008), emotional functioning (P=0.0001) and social functioning (P=0.012), whereas the patients' own assessment of global QOL (item global QOL in functioning scales) did not show the same evolution. CONCLUSION Disclosure of the diagnosis had an impact on social and emotional QOL. Patients with lung cancer need psychological support at the beginning of their disease.
Collapse
Affiliation(s)
- M Lheureux
- Service des Maladies Respiratoires, Hôpital du Haut Lévêque, CHU-Bordeaux, 5 Avenue de Magellan, 33604 Pessac, France
| | | | | | | | | | | | | |
Collapse
|
12
|
Nguyen L, Raherison C, Bozonnat MC, Lheureux M, Nocent C, Tunon-de-Lara JM, Taytard A. [Validation of an asthma knowledge questionnaire]. Rev Mal Respir 2003; 20:871-80. [PMID: 14743088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/28/2023]
Abstract
INTRODUCTION A patient's knowledge of his disease and its treatment is an essential part of the evaluation of an educational process. It is useful therefore to use a rapid, easy and valid means of collecting the information necessary to produce an educational programme adapted to the needs of the patient. METHODS Following a review of the literature an initial questionnaire was constructed. It included four domains: biomedical, signs and symptoms of severity, general knowledge and treatment. The questionnaire was administered to 73 asthmatics in order to assess its clarity and comprehensibility. It was then reviewed and modified in both format and content by 10 French experts. The revised questionnaire was completed by 108 asthmatics distributed throughout 10 French respiratory centres, a group of 83 non-asthmatic subjects and 203 sixth year medical students at the Bordeaux University School of Medicine. RESULTS The mean scores were: 19 for the non-asthmatics (range 2-36), 25.7 for the asthmatics (range 4-38) and 32.9 for the students (range 17-40), p 0.0001. The questionnaire was shown to be discriminating with good reliability and reproducibility: alpha Cronbach coefficient=0.82; intra-class correlation coefficient=0.70. CONCLUSIONS This study has validated a French language asthma knowledge questionnaire.
Collapse
Affiliation(s)
- L Nguyen
- Service des Maladies Respiratoires, Hôpital du Haut Lévêque, CHU de Bordeaux, Pessac, France.
| | | | | | | | | | | | | |
Collapse
|
13
|
Raherison C, Nocent C, Tunon De Lara JM, Latrabe V, Laurent F, Taytard A. [Mediastinal sarcoidosis and vascular thrombosis: a fortuitous association?]. Rev Mal Respir 2001; 18:63-5. [PMID: 14639179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/27/2023]
Abstract
A 43-year-old woman presented with a recent history of intermittent dyspnea with wheezing. The chest x-ray evidenced mediastinal nodes. A CT scan showed vascular embolism. Mediastinoscopy was performed and pathology examination of the node confirmed the diagnosis of sarcoidosis. The patient responded to corticosteroid and anticoagulation therapy. Is this a fortuitous association? A vascular localization of sarcoidosis? Thrombosis by compression?
Collapse
Affiliation(s)
- C Raherison
- Service des Maladies Respiratoires, CHU Haut-Lévèque, 33604 Pessac
| | | | | | | | | | | |
Collapse
|